Medical Device News Magazine

Jian Zhang, CEO & Founder, Noah Medical Article: Importance of Investing in Healthcare and MedTech R&D

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Jian Zhang: Technology has always been a vital ally for healthcare. From diagnostic capabilities finding disease earlier to therapies that increase the quality of care, improve clinical efficiency, and lower cost. But healthcare has been slow to adopt technology because innovation can be long,  incremental, and path-dependent. This is especially true when examining investment in research and development (R&D), a crucial component of the development of tech-enabled solutions.

This is typified by medical robotics. The healthcare robotics landscape is primed for dramatic change and an influx of new entrants over the coming decade with the industry projected to be $20B by 2030. The first generation of pioneering robotic technologies has paved the way for new technologies that aim to fill growing innovation gaps in medical applications. From diagnostic and surgical robots to those used in novel ways – these new opportunities will launch a boom in companies coming to market or expanding their current offerings.

In turn, this could set off a corresponding arms race in R&D efforts to counter the slow investment to date. That will create fierce competition amongst both new entrants and established players for three valuable resources – funding, talent and facilities.

If healthcare robotics follows trendlines in medical devices and medtech, R&D investment might also become a prerequisite to a successful commercial adoption. In the traditional medtech sector, the preponderance of acquirers essentially outsource their R&D and early commercialization efforts to others, allowing startups and innovators to identify openings and build early traction before snapping them up. This historical trend may be disrupted by the new technology startups and new waves of fundings that are investing for the long term.

In this R&D battle, healthcare robotics leaders should work early to differentiate themselves within the market and create a defensible beach head as they compete for:

Funding 

Healthcare robotics is a capital intensive business, and new numbers reflect the growing attention being paid to the sector by investors. According to CB Insights, medical device deals grew 63% to top $5 billion in funding for the first time in the third quarter of 2020. Surgical robotics deals were a significant driver of that volume. A surgical robotics maker also cracked the top ten in UK and US healthcare venture deals in 2021 with CMR Surgical securing $600M in a Series D for fifth place on the list. And there is a lot of related movement with announcements like Intuitive’s creation of a $100M venture fund for early stage surgical robotics companies.

Talent 

While funding may be readily available, talent is in shorter supply. Technology fields have faced a lack of available talent to fill open roles for years, and the competition for robotics engineers and staff comes at an even greater premium. This is reflected in the broader robotics field where Korn Ferry predicts that companies might have to invest in re-skilling efforts to fill positions, especially those based in rural areas since talent tends to migrate to urban centers. From engineers to software developers to machinists, competition for healthcare robotics talent will be fierce and companies should be prepared to spend considerable time and resources to attract the very best.

Facilities 

Unlike healthtech applications that leverage wearables or digital platforms, robotics often requires testing and proving in relation to a physical environment. It also demands rigorous production facilities and standards. Not to mention testing capabilities to secure FDA clearance. All that means real estate – and lots of it.  Just in the case of Noah Medical, we’ve already secured, updated and opened two new facilities in addition to our existing 12,000 sq ft headquarters in the Bay Area. This space is critical as we develop, test and build our future technologies.

It’s difficult to discern industry winners or determine momentum based on funding announcements alone because it’s easy to create hype around smaller or early funding rounds, or simply because some important players are being stealthy about their fundraising efforts. Given this, perhaps a more grounded way to measure a company’s success may be to look at  the pool of talent that chooses to work there or their approach to brick and mortar expansion.

Editor’s Note: About the author Jian Zhang:

Jian is a serial entrepreneur. Prior to Noah Medical, Jian also co-founded two other successful startups and served as the CEO. In addition, he was employee #2 at Auris Health, which was acquired by Johnson & Johnson for $5.7B in 2019. Prior to joining Auris, he worked at Intuitive Surgical. Jian received his MS and PhD from Columbia University.

 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

The HeartFlow Plaque Analysis uses proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, creating a personalized 3D model that quantifies and characterizes plaque volume in the coronary arteries, aiding risk assessment of coronary artery disease. The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C.